Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × LY2584702 × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 NET 1 Genitourinary 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Everolimus 2 regorafenib 1 exemestane 1 entrectinib 1 cabozantinib 1 Nivolumab 1 LY2584702 1 Injections 1 Erlotinib Hydrochloride 1 Clinical Trials, Phase II as Topic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Terminated

29 enrolled 19 charts

EndocrineGenitourinaryNETThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡